Argenx

Kalender

	Est. tid*
2026-10-27	N/A	Kvartalsrapport 2026-Q3
2026-07-27	N/A	Kvartalsrapport 2026-Q2
2026-05-08	N/A	Kvartalsrapport 2026-Q1
2026-03-09	N/A	Bokslutskommuniké 2025
2025-10-30	N/A	Kvartalsrapport 2025-Q3
2025-07-31	N/A	Kvartalsrapport 2025-Q2
2025-05-27	-	Årsstämma
2025-05-08	-	Kvartalsrapport 2025-Q1
2025-02-27	-	Bokslutskommuniké 2024
2024-10-31	-	Kvartalsrapport 2024-Q3
2024-07-25	-	Kvartalsrapport 2024-Q2
2024-05-09	-	Kvartalsrapport 2024-Q1
2024-05-07	-	Årsstämma
2024-03-21	-	Bokslutskommuniké 2023
2024-02-29	-	Bokslutskommuniké 2023
2023-10-31	-	Kvartalsrapport 2023-Q3
2023-07-27	-	Kvartalsrapport 2023-Q2
2023-05-04	-	Kvartalsrapport 2023-Q1
2023-05-02	-	Årsstämma
2023-03-02	-	Bokslutskommuniké 2022
2023-02-27	-	Extra Bolagsstämma
2022-10-27	-	Kvartalsrapport 2022-Q3
2022-09-08	-	Extra Bolagsstämma
2022-07-28	-	Kvartalsrapport 2022-Q2
2022-05-10	-	Årsstämma
2022-05-05	-	Kvartalsrapport 2022-Q1
2022-03-03	-	Bokslutskommuniké 2021
2021-10-28	-	Kvartalsrapport 2021-Q3
2021-07-29	-	Kvartalsrapport 2021-Q2
2021-05-14	-	Kvartalsrapport 2021-Q1
2021-03-31	-	Bokslutskommuniké 2020
2020-10-22	-	Kvartalsrapport 2020-Q3
2020-07-30	-	Kvartalsrapport 2020-Q2
2020-05-14	-	Kvartalsrapport 2020-Q1
2020-05-12	-	Årsstämma
2019-11-25	-	Extra Bolagsstämma

Filter

År

Typ

Språk

Rensa

2025-06-30 07:00:00 argenx Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes 471,65 EUR | -1,75%

2025-06-20 19:00:00 argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy 475,25 EUR | +1,17%

2025-06-11 00:01:00 argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren’s Disease 507,05 EUR | -1,24%

2025-06-03 07:00:00 argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference 510,70 EUR | +1,47%

2025-05-28 22:01:00 argenx Announces Results of Annual General Meeting of Shareholders 512,05 EUR | -0,37%

2025-05-08 07:00:00 argenx Reports First Quarter 2025 Financial Results and Provides Business Update 484,65 EUR | -10,91%

2025-05-06 07:00:00 argenx to Present at BofA Securities 2025 Health Care Conference 568,40 EUR | -0,99%

2025-05-01 07:00:00 argenx to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025 559,70 EUR | 0,00%

2025-04-28 07:00:00 argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) 541,40 EUR | +1,46%

2025-04-11 22:01:00 argenx Announces Annual General Meeting of Shareholders on May 27, 2025 504,65 EUR | +1,07%

2025-04-10 23:47:43 argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy 504,65 EUR | +1,07%

2025-04-08 07:00:00 argenx Highlights VYVGART Data at AAN 2025 Setting New Standard in Sustained Efficacy and Improved Quality of Life Measures for Patients Living with gMG and CIDP 517,55 EUR | +4,05%

2025-03-07 07:00:00 argenx Highlights FcRn Leadership with Long-term Data and Transformational Patient Outcomes at the American Academy of Neurology 2025 Annual Meeting 555,50 EUR | -4,57%

2025-02-27 07:00:00 argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update 615,70 EUR | +3,06%

2025-02-25 07:00:00 argenx to Present at TD Cowen 45th Annual Healthcare Conference 608,00 EUR | -0,69%

2025-02-20 07:00:00 argenx to Report Full Year 2024 Financial Results and Fourth Quarter Business Update on February 27, 2025 608,60 EUR | -0,62%

2025-01-13 07:00:00 argenx Highlights 2025 Strategic Priorities 638,50 EUR | -1,30%

2025-01-06 07:00:00 argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference 607,30 EUR | +0,35%

2024-12-27 07:00:00 argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy 601,20 EUR | +0,74%

2024-11-26 07:00:00 argenx to Present at Upcoming Investor Conferences 584,00 EUR | +1,07%

2024-11-20 07:00:00 argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies 565,20 EUR | +5,29%

2024-11-11 13:30:00 argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China 558,30 EUR | +1,62%

2024-11-05 07:00:00 argenx to Participate at Upcoming Investor Conferences 540,60 EUR | -0,28%

2024-10-31 07:00:00 argenx Reports Third Quarter 2024 Financial Results and Provides Business Update 539,70 EUR | +5,04%

2024-10-24 07:00:00 argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024 511,70 EUR | -2,21%

2024-10-15 07:00:00 argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scientific Sessions 503,85 EUR | +0,95%

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Argenx

Kalender

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden